HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nina Shah Selected Research

idecabtagene vicleucel

1/2022Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
1/2022Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
3/2021Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
1/2021Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
1/2021KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nina Shah Research Topics

Disease

64Multiple Myeloma
12/2022 - 01/2012
21Neoplasms (Cancer)
01/2022 - 09/2007
12Hematologic Neoplasms (Hematological Malignancy)
11/2021 - 12/2014
9Graft vs Host Disease (Graft-Versus-Host Disease)
10/2020 - 10/2013
6Infections
12/2022 - 02/2002
5Plasma Cell Leukemia
01/2022 - 01/2019
4Residual Neoplasm
10/2021 - 02/2017
4Lymphoma (Lymphomas)
01/2017 - 01/2012
3Pain (Aches)
01/2022 - 02/2005
3Immunoglobulin Light-chain Amyloidosis
01/2022 - 01/2012
3Cytokine Release Syndrome
11/2021 - 01/2021
3Fever (Fevers)
01/2021 - 01/2002
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 09/2010
3Disease Progression
11/2019 - 10/2013
3Mucositis
05/2019 - 01/2016
3Hodgkin Disease (Hodgkin's Disease)
01/2016 - 11/2012
3Inflammation (Inflammations)
02/2015 - 02/2005
3HIV Infections (HIV Infection)
05/2006 - 02/2002
2Pneumonia (Pneumonitis)
01/2020 - 01/2002
2Dermatitis
06/2017 - 01/2016
2Pure Red-Cell Aplasia
05/2016 - 03/2013
2Amyloidosis
02/2016 - 01/2012
2Peripheral Nervous System Diseases (PNS Diseases)
10/2014 - 06/2013
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
09/2014 - 06/2014
2Body Weight (Weight, Body)
04/2014 - 12/2012
2Non-Hodgkin Lymphoma (Lymphosarcoma)
11/2012 - 01/2012
2Oral Candidiasis (Thrush)
02/2002 - 01/2002
2Anemia
02/2002 - 01/2002
1Injection Site Reaction
12/2022
1Lymphopenia (Lymphocytopenia)
12/2022
1Neutropenia
12/2022
1Hypersensitivity (Allergy)
12/2022
1POEMS Syndrome (Syndrome, POEMS)
12/2022
1Fatigue
01/2022
1Macrophage Activation Syndrome
12/2021
1cell-associated neurotoxicity
01/2021
1Brain Diseases (Brain Disorder)
01/2021
1Hemorrhage
01/2021
1Thrombocytopenia (Thrombopenia)
01/2021
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2021
1Venous Thrombosis (Deep-Vein Thrombosis)
01/2021
1Mitochondrial Diseases (Mitochondrial Disease)
01/2021
1Cardiotoxicity
12/2020
1Necrosis
10/2020

Drug/Important Bio-Agent (IBA)

14Chimeric Antigen ReceptorsIBA
12/2022 - 01/2019
11Melphalan (Alkeran)FDA LinkGeneric
05/2019 - 01/2012
8Busulfan (Busulfex)FDA Link
05/2019 - 11/2012
7B-Cell Maturation AntigenIBA
12/2022 - 01/2020
6bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
12/2022 - 01/2020
6Pharmaceutical PreparationsIBA
12/2022 - 04/2002
6Lenalidomide (CC 5013)FDA Link
01/2022 - 06/2014
5daratumumabIBA
12/2022 - 01/2020
5trans-crotonin (CTN)IBA
10/2022 - 01/2019
5idecabtagene vicleucelIBA
01/2022 - 01/2021
5Proteasome InhibitorsIBA
01/2021 - 09/2017
4Dexamethasone (Maxidex)FDA LinkGeneric
01/2022 - 01/2019
4Bortezomib (Velcade)FDA Link
01/2022 - 05/2012
4Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 03/2013
4Monoclonal AntibodiesIBA
10/2021 - 01/2020
3Rituximab (Mabthera)FDA Link
09/2021 - 11/2015
3carfilzomibIBA
01/2021 - 01/2020
3AntigensIBA
01/2020 - 07/2015
3DNA (Deoxyribonucleic Acid)IBA
01/2020 - 01/2016
3fludarabineIBA
01/2019 - 10/2013
3GemcitabineFDA Link
06/2017 - 11/2012
2venetoclaxIBA
01/2022 - 01/2020
2Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2020
2Immunomodulating AgentsIBA
01/2020 - 09/2017
2MethyltransferasesIBA
01/2020 - 01/2016
2FM 100 (FM100)IBA
01/2019 - 10/2013
2SteroidsIBA
01/2018 - 04/2014
2Tacrolimus (Prograf)FDA LinkGeneric
11/2016 - 03/2013
2Amyloid (Amyloid Fibrils)IBA
02/2016 - 01/2012
2VorinostatFDA Link
01/2016 - 11/2015
2Gonadal Steroid Hormones (Sex Hormones)IBA
05/2006 - 02/2005
2Zidovudine (Retrovir)FDA LinkGeneric
02/2002 - 01/2002
1lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)IBA
12/2022
1ProteomeIBA
01/2022
1elotuzumabIBA
10/2021
1NKTR-255IBA
09/2021
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
09/2021
1Interleukin-15 (Interleukin 15)IBA
09/2021
1isatuximabIBA
01/2021
1tocilizumab (atlizumab)FDA Link
01/2021
1eltrombopagFDA Link
01/2021
1Biomarkers (Surrogate Marker)IBA
01/2021
1Proteasome Endopeptidase Complex (Proteasome)IBA
12/2020
1CalciumIBA
10/2020
1Vitamin DFDA LinkGeneric
10/2020

Therapy/Procedure

41Therapeutics
12/2022 - 05/2003
19Transplantation
01/2022 - 11/2012
18Cell Transplantation
12/2022 - 03/2013
18Hematopoietic Stem Cell Transplantation
11/2021 - 03/2012
17Drug Therapy (Chemotherapy)
03/2022 - 07/2012
11Stem Cell Transplantation
03/2022 - 09/2010
5Autologous Transplantation
01/2022 - 01/2018
5Immunotherapy
01/2021 - 06/2015
2Blood Component Removal (Apheresis)
01/2017 - 07/2011
1Salvage Therapy
01/2022
1Wearable Electronic Devices
01/2021